Table 4.
Genotype frequencies and drug-resistance odds ratio for ABCB1-T129C and -T1236C polymorphisms in Iranian epileptic patients.
| P |
OR
(95% CI) |
Drug-resistant
patients |
Drug-responsive
patients |
Genotype | Subgroups of age |
|---|---|---|---|---|---|
| 0.75 | 1.21 (0.36-4.06) 1 |
0 5 (3.75%) 127 (96.25%) |
0 7 (3.5%) 193 (96.5%) |
CC CT TT |
ABCB1-T129C (n = 332) |
| 0.75 | 1.21 (0.36-4.06) 1 |
0 5 (3.84%) 125 (96.15%) |
0 6 (3.19%) 182 (96.8%) |
CC CT TT |
Adults (n = 318) |
| small sample size | 0 0 4 (100%) |
0 1 (10%) 9 (90%) |
CC CT TT |
Children (n = 14) |
|
| 0.11 0.19 |
1.73 (0.88-3.41) 1.39 (0.85-3.41) 1 |
24 (18.18%) 65 (49.24%) 43 (32.57%) |
28 (14%) 87 (43.5%) 85 (42.5%) |
CC CT TT |
ABCB1-T1236C (n = 332) |
| 0.11 0.19 |
1.73 (0.88-3.41) 1.39 (0.85-3.41) 1 |
23 (17.96%) 62 (48.43%) 43 (33.59%) |
25 (13.15%) 84 (44.21%) 81 (42.63%) |
CC CT TT |
Adults (n = 318) |
| small sample size | 1 (25%) 3 (75%) 0 |
3 (30%) 3 (30%) 4 (40%) |
CC CT TT |
Children (n = 14) |